Streetbeat News

Analyst Ratings

AR

Antero Resources (NYSE:AR) has been analyzed by 7 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $28.00, down 7.68% from the previous target. Analyst actions include both upgrades and downgrades, reflecting varying perspectives on the company's performance. Antero Resources, engaged in natural gas and liquids production, faces challenges with lower market capitalization, revenue decline of -38.57%, and below-average profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:01 pm

PLXS

Analysts have diverse opinions on Plexus (NASDAQ:PLXS), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $109.8, down from $111.50. Plexus faces revenue challenges with a -10.18% decline as of December 31, 2023, but outperforms in net margin, ROE, and ROA. The company's debt management is also noted positively.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:00 pm

TYL

Tyler Technologies (NYSE:TYL) has received mixed analyst ratings over the past three months, with a total of 10 ratings ranging from bullish to bearish. The average 12-month price target for TYL has increased by 5.3% to $491.5. Analyst actions include maintaining, raising, and announcing ratings, with price targets adjusted accordingly. Tyler Technologies, a provider of software solutions for local government entities, has shown a revenue growth of 6.35% as of December 31, 2023, but trails behind industry peers in profitability and efficiency metrics.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 7:00 pm

IFF

Argus Research analyst John Eade downgraded Intl Flavors & Fragrances (IFF) from Buy to Hold, indicating a shift in the firm's outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:59 pm

RWAY

Oppenheimer analyst Mitchel Penn downgraded Runway Growth Finance (RWAY) from Outperform to Perform.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:58 pm

AMLX

Evercore ISI Group analyst Umer Raffat downgraded Amylyx Pharma (NASDAQ:AMLX) from Outperform to In-Line, indicating a change in the stock's expected performance.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:55 pm

SWBI

Craig-Hallum analyst Steve Dyer upgrades Smith & Wesson Brands (SWBI) from Hold to Buy and increases the price target from $14 to $18.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:52 pm

GIFI

Johnson Rice analyst Martin Malloy has upgraded Gulf Island Fabrication (NASDAQ:GIFI) from Hold to Accumulate, indicating a more positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:49 pm

ALXO

ALX Oncology Holdings (NASDAQ:ALXO) reported a Q4 2023 EPS loss of $(0.93), missing consensus estimates. Despite sufficient funds to operate into early 2026 and promising interim Phase 2 data for its cancer treatment, evorpacept, Stifel downgraded the stock from Buy to Hold. The downgrade reflects concerns over the limited market size for HER2+ gastric cancer and uncertainties in development paths for other cancers. ALXO shares dropped 3.51% to $15.67.

Portfolio Pulse from Vandana Singh

March 08, 2024 | 6:48 pm

NEPH

Benchmark analyst Robert Wasserman upgrades Nephros (NASDAQ:NEPH) from Hold to Speculative Buy and sets a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 6:46 pm